More MS news articles for June 2002

Biogen and SurroMed Announce Collaborative Research Agreement for Comprehensive Phenotyping and Biological Marker Discovery

Research Program to Focus on Multiple Sclerosis and Patient Response to Biogen's AVONEX(R)

Thursday June 20, 7:00 am Eastern Time
Press Release
SOURCE: SurroMed, Inc.

MOUNTAIN VIEW, Calif., June 20 /PRNewswire/ -- SurroMed, Inc. today announced that it has entered into a two-year collaborative research agreement with Biogen, Inc. (Nasdaq: BGEN - News) to study patients with multiple sclerosis (MS) and characterize patient responses to Biogen's AVONEX® (Interferon-beta-1a). SurroMed will use its proprietary, integrated platform for biological marker discovery and comprehensive phenotyping to identify biological markers that are useful for discovering and developing new MS drugs and that can be commercialized as diagnostic tests to guide and improve MS patient care and treatment.

Under the agreement, Biogen and SurroMed will undertake clinical research, and SurroMed will analyze patient samples in its Biomarker Discovery Laboratory using its proprietary systems and methods for advanced proteomic, metabolomic and cytometric analysis. SurroMed will integrate, analyze and mine study data using its proprietary suite of informatics tools to identify biological markers and disease pathways.

Under the terms of the collaboration, SurroMed will receive research funding, a technology access fee, and success payments contingent upon achievement of certain objectives. In addition, SurroMed will receive revenues from sales of diagnostic tests discovered under the agreement. Additional financial terms were not disclosed.

"We are delighted to have the opportunity to collaborate with Biogen, the worldwide leader in MS therapeutics," said Gordon Ringold, Ph.D., CEO and Chairman of SurroMed. "We look forward to combining SurroMed's unique biomarker discovery and comprehensive phenotyping capabilities with Biogen's extensive expertise and experience in MS to better understand disease pathways and individual patient response to therapy."

Burt Adelman, M.D., Biogen's Executive Vice President of Research and Development, said "Biogen is committed to continuing to provide and develop the best therapeutics for patients with MS. We are pleased to access SurroMed's cutting-edge technology in this collaboration, another example of our determination to understand the basis of this disease and how best to treat it."

About SurroMed, Inc.

Headquartered in Mountain View, California, SurroMed focuses on discovering and applying biological markers to (i) improve the drug discovery and development process; and (ii) enable the precise diagnosis and personalized treatment of disease. SurroMed uses its platform for biological marker discovery and comprehensive phenotyping to discover root causes of disease, the molecular basis for patient-to-patient variations in disease presentation, progression and response to therapy, and to understand how drugs work. SurroMed's research process yields biological markers and information that enable accelerated, cost-efficient discovery and development of new therapeutic products, as well as development of diagnostics tests for early disease detection, disease staging and stratification, and guiding and monitoring therapy. SurroMed's platform for biological marker discovery and comprehensive phenotyping incorporates proprietary advanced technologies for profiling and analyzing thousands of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples. By capturing, integrating and analyzing large amounts of clinical and biological information-at the level of the cell, gene, protein, and low-molecular-weight organic molecule-SurroMed identifies useful biological markers and provides a complete picture of the pathways involved in disease and therapeutic response.

SOURCE: SurroMed, Inc.

Copyright © 2002 Yahoo! Inc